GlassScriptPhysician profile
Olga Vitorsky
NPI 1174055271
$3,548.09
in general payments reported to CMS, 2019-2025
27 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.87 · 2021: $255 · 2023: $600 · 2024: $1,106 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,212 · Education: $41.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.70 |
| Education | $41.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $897.46 | 2023-2025 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $369.74 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.54 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Ipsen Biopharmaceuticals, INC | $244.36 | 2024-2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $210.31 | 2024-2025 | Entyvio, Eohilia |
| Medtronic, INC. | $179.12 | 2021-2025 | Gi Genius, Interstim |
| Phathom Pharmaceuticals, INC. | $177.46 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $155.76 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $140.99 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $137.86 | 2019-2021 | |
| Madrigal Pharmaceuticals | $106.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $86.38 | 2024-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $83.88 | 2023-2024 | Rebyota |
| Pfizer INC. | $73.92 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $70.51 | 2023-2025 | Ocaliva |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.26 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $45.09 | 2023-2024 | Linzess |
| Celltrion USA INC. | $32.14 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $30.66 | 2023-2024 | Dificid |
| Aimmune Therapeutics, INC. | $29.05 | 2025 | Zenpep |
| Boston Scientific Corporation | $27.08 | 2025 | Apollo Esg Nxt System |
| Gilead Sciences, INC. | $25.90 | 2024 | |
| Biocon Biologics INC | $23.97 | 2025 | Yesintek |
| Celgene Corporation | $21.46 | 2021 | |
| Lilly USA, LLC | $19.07 | 2024 | Omvoh |
| Qol Medical, LLC | $18.13 | 2023 | Sucraid |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Vitorsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.